CN113966326A - 水溶性佐剂 - Google Patents

水溶性佐剂 Download PDF

Info

Publication number
CN113966326A
CN113966326A CN202080041623.7A CN202080041623A CN113966326A CN 113966326 A CN113966326 A CN 113966326A CN 202080041623 A CN202080041623 A CN 202080041623A CN 113966326 A CN113966326 A CN 113966326A
Authority
CN
China
Prior art keywords
compound
methyl
vaccine
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080041623.7A
Other languages
English (en)
Chinese (zh)
Inventor
坂仁志
高梨洋辅
后藤正志
杉边奈津子
今崎雄介
岩田佳子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of CN113966326A publication Critical patent/CN113966326A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN202080041623.7A 2019-04-05 2020-04-03 水溶性佐剂 Pending CN113966326A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019072910 2019-04-05
JP2019-072910 2019-04-05
PCT/JP2020/015359 WO2020204172A1 (ja) 2019-04-05 2020-04-03 水溶性アジュバント

Publications (1)

Publication Number Publication Date
CN113966326A true CN113966326A (zh) 2022-01-21

Family

ID=72668226

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080041623.7A Pending CN113966326A (zh) 2019-04-05 2020-04-03 水溶性佐剂

Country Status (8)

Country Link
US (1) US12427192B2 (https=)
EP (1) EP3949983A4 (https=)
JP (1) JP7539867B2 (https=)
KR (1) KR102921677B1 (https=)
CN (1) CN113966326A (https=)
CA (1) CA3136182A1 (https=)
MX (1) MX2021012201A (https=)
WO (1) WO2020204172A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022327884A1 (en) * 2021-08-12 2024-02-22 International Institute Of Cancer Immunology, Inc. Pharmaceutical composition and method for treatment or prevention of cancer
US20240115503A1 (en) * 2021-11-17 2024-04-11 Lipella Pharmaceuticals Inc. Intravesical delivery of hydrophilic therapeutic agents using liposomes
US12036318B2 (en) * 2022-02-16 2024-07-16 Chemical & Schutz High Performance Lubricants, S.A. De C.V. Self-emulsionable mineral oil as a vehicle in vaccines for poultry

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108290845A (zh) * 2015-10-07 2018-07-17 大日本住友制药株式会社 嘧啶化合物
WO2018132496A1 (en) * 2017-01-10 2018-07-19 Nektar Therapeutics Multi-arm polymer conjugates of tlr agonist compounds and related immunotherapeutic treatment methods
WO2018181420A1 (ja) * 2017-03-29 2018-10-04 大日本住友製薬株式会社 ワクチンアジュバント製剤

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06002199A (es) * 2003-08-27 2006-05-22 3M Innovative Properties Co Imidazoquinolinas sustituidas con grupos ariloxi o arilalquilenoxi.
WO2006078059A1 (ja) 2005-01-19 2006-07-27 Dainippon Sumitomo Pharma Co., Ltd. 希釈用乳化組成物および癌ワクチン組成物
ES2352855T3 (es) 2005-11-30 2011-02-23 International Institute Of Cancer Immunology, Inc. Nuevos compuestos peptídicos del tumor de wilms.
PE20091236A1 (es) 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
KR20110117705A (ko) * 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 톨-유사 수용체 조정제 및 질병의 치료
JO3257B1 (ar) * 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
ES2458355T3 (es) 2010-09-01 2014-05-05 Novartis Ag Adsorción de inmunopotenciadores sobre sales metálicas insolubles
WO2012066336A1 (en) 2010-11-19 2012-05-24 Astrazeneca Ab Benzylamine compounds as toll -like receptor 7 agonists
MY171854A (en) 2013-03-29 2019-11-05 Sumitomo Dainippon Pharma Co Ltd Wt1 antigen peptide conjugate vaccine
EP2980097A4 (en) 2013-03-29 2017-03-08 Sumitomo Dainippon Pharma Co., Ltd. Conjugate vaccine using trimming function of erap1
WO2017102652A1 (en) 2015-12-14 2017-06-22 Glaxosmithkline Biologicals S.A. Pegylated imidazoquinolines as tlr7 and tlr8 agonists
EP3510036B1 (en) * 2016-09-07 2021-07-21 GlaxoSmithKline Biologicals SA Imidazoquinoline derivatives and their use in therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108290845A (zh) * 2015-10-07 2018-07-17 大日本住友制药株式会社 嘧啶化合物
WO2018132496A1 (en) * 2017-01-10 2018-07-19 Nektar Therapeutics Multi-arm polymer conjugates of tlr agonist compounds and related immunotherapeutic treatment methods
WO2018181420A1 (ja) * 2017-03-29 2018-10-04 大日本住友製薬株式会社 ワクチンアジュバント製剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XIN CHANG等: "Conjugation of PEG-hexadecane markedly increases the immunogenicity of pneumococcal polysaccharide conjugate vaccine", VACCINE, 31 December 2016 (2016-12-31), pages 1698 *

Also Published As

Publication number Publication date
US20220211844A1 (en) 2022-07-07
EP3949983A4 (en) 2022-12-21
KR102921677B1 (ko) 2026-02-02
EP3949983A1 (en) 2022-02-09
JPWO2020204172A1 (https=) 2020-10-08
KR20220004637A (ko) 2022-01-11
JP7539867B2 (ja) 2024-08-26
WO2020204172A1 (ja) 2020-10-08
MX2021012201A (es) 2022-01-06
AU2020251582A1 (en) 2021-12-02
CA3136182A1 (en) 2020-10-08
US12427192B2 (en) 2025-09-30

Similar Documents

Publication Publication Date Title
JP7253210B2 (ja) Ｗｔ１抗原ペプチドおよび免疫調節剤の併用
JP7248261B2 (ja) 癌を処置するための医薬組成物
KR102921677B1 (ko) 수용성 보조제
WO2018181648A1 (ja) Ｗｔ１癌抗原ペプチドおよびこれを含むペプチドコンジュゲート体
JP7209963B2 (ja) Ｗｔ１ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ
CN105658673B (zh) 新型的具有4个连接的ctl表位的肽
JP7573516B2 (ja) 水溶性アジュバントおよびそれを含有する組成物
JPWO2019131722A1 (ja) Ｗｔ１由来ペプチドのコンジュゲート体およびこれを含む組成物
AU2020251582B2 (en) Water soluble adjuvant
HK40068431A (en) Water soluble adjuvant
CN116056721A (zh) 具有tlr4激动剂活性的佐剂
HK40068589A (en) Water soluble adjuvant and composition containing same
HK40084495A (en) Pharmaceutical composition for treating cancer
HK40032856A (en) Conjugate of wt1-derived peptides and composition comprising the same
HK1250213B (en) Combination of wt1 antigen peptide, immunomodulator and wt1 helper peptide
HK1224680A1 (en) Novel four-ctl epitope-joined peptide

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Osaka City, Osaka of Japan

Applicant after: SUMITOMO PHARMACEUTICALS CO.,LTD.

Address before: Osaka City, Osaka of Japan

Applicant before: Dainippon Sumitomo Pharma Co.,Ltd.

CB02 Change of applicant information
CB02 Change of applicant information

Address after: No. 6-8, Doshucho 2-chome, Chuo-ku, Osaka City, Osaka Prefecture, Japan

Applicant after: SUMITOMO PHARMACEUTICALS CO.,LTD.

Address before: Osaka City, Osaka of Japan

Applicant before: SUMITOMO PHARMACEUTICALS CO.,LTD.

CB02 Change of applicant information